0
0
LA JOLLA, CA – A compound derived from common herbs like rosemary and sage is showing significant potential in combating Alzheimer’s disease, according to new research from Scripps Research. Scientists have synthesized a stable form of carnosic acid, a natural antioxidant and anti-inflammatory found in these herbs, which has demonstrated remarkable effects in mouse models of Alzheimer’s.
The study, published in the journal Antioxidants, focused on diAcCA, a synthesized version of carnosic acid that converts to the active compound in the gut. Researchers found that diAcCA effectively delivered therapeutic doses of carnosic acid to the brains of mice with Alzheimer’s, leading to enhanced memory, increased synaptic density (connections between nerve cells), and a significant reduction in brain inflammation.
“By combating inflammation and oxidative stress with this diAcCA compound, we actually increased the number of synapses in the brain,” said senior author and professor Stuart Lipton, MD, Ph.D., of Scripps Research. “We also took down other misfolded or aggregated proteins such as phosphorylated-tau and amyloid-β, which are thought to trigger Alzheimer’s disease and serve as biomarkers of the disease process.”
One of the key advantages of diAcCA is its targeted action. The compound is activated by inflammation, meaning it primarily works in areas of the brain that are already damaged. This selectivity minimizes potential side effects, especially considering carnosic acid is considered generally safe by the U.S. Food and Drug Administration (FDA).
The research team conducted extensive testing, including behavioral tests to assess spatial learning and memory, and microscopic analysis of brain tissue. Results showed that diAcCA not only slowed cognitive decline but also improved memory function in the mice, nearly returning it to normal levels.
Furthermore, toxicity studies revealed that diAcCA was well-tolerated by the mice and even helped soothe baseline inflammation in the digestive tract. The compound also proved more efficient at delivering carnosic acid to the bloodstream compared to directly ingesting the natural compound.
Professor Lipton believes diAcCA could be used in conjunction with existing Alzheimer’s treatments, potentially enhancing their effectiveness and reducing side effects. He also sees potential for diAcCA to treat other inflammatory conditions, such as type 2 diabetes, heart disease, and Parkinson’s disease.
The research team now hopes to fast-track diAcCA through clinical trials, given its promising safety profile.
Disclaimer: This article is based on research conducted on mouse models and published in the journal Antioxidants. While the results are promising, further research and clinical trials are necessary to determine the safety and efficacy of diAcCA in humans. This information should not be interpreted as medical advice. Always consult with a healthcare professional before making any decisions related to your health or treatment.
